News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
454,625 Results
Type
Article (50721)
Company Profile (117)
Press Release (403787)
Section
Business (126167)
Career Advice (1580)
Deals (17968)
Drug Delivery (60)
Drug Development (58432)
Employer Resources (106)
FDA (9851)
Job Trends (10497)
News (213301)
Policy (17553)
Tag
Academia (2747)
Alliances (36515)
Alzheimer's disease (1155)
Approvals (9852)
Artificial intelligence (124)
Bankruptcy (117)
Best Places to Work (8355)
Breast cancer (145)
Cancer (1181)
Cardiovascular disease (83)
Career advice (1293)
CAR-T (86)
Cell therapy (225)
Clinical research (45947)
Collaboration (456)
COVID-19 (2083)
C-suite (78)
Data (1161)
Diabetes (110)
Diagnostics (4243)
Earnings (44205)
Employer resources (93)
Events (58463)
Executive appointments (301)
FDA (10354)
Funding (355)
Gene therapy (149)
GLP-1 (404)
Government (2794)
Healthcare (13839)
Infectious disease (2157)
Inflammatory bowel disease (83)
Interviews (302)
IPO (8345)
Job creations (2463)
Job search strategy (1129)
Layoffs (250)
Legal (3073)
Lung cancer (171)
Lymphoma (83)
Manufacturing (143)
Medical device (7963)
Medtech (7966)
Mergers & acquisitions (9813)
Metabolic disorders (290)
Neuroscience (1418)
NextGen: Class of 2025 (4551)
Non-profit (4167)
Northern California (1209)
Obesity (144)
Opinion (138)
Parkinson's disease (81)
Patents (76)
People (35973)
Phase I (14242)
Phase II (20137)
Phase III (15120)
Pipeline (487)
Postmarket research (2056)
Preclinical (7014)
Radiopharmaceuticals (169)
Rare diseases (189)
Real estate (4730)
Regulatory (12716)
Research institute (2533)
Resumes & cover letters (242)
Southern California (1021)
Startups (2413)
United States (10635)
Vaccines (468)
Weight loss (92)
Date
Today (83)
Last 7 days (521)
Last 30 days (1312)
Last 365 days (23225)
2025 (843)
2024 (23415)
2023 (27059)
2022 (36960)
2021 (39261)
2020 (37119)
2019 (32276)
2018 (24391)
2017 (21664)
2016 (21699)
2015 (25444)
2014 (19320)
2013 (17092)
2012 (17397)
2011 (18111)
2010 (16636)
Location
Africa (599)
Arizona (104)
Asia (27982)
Australia (5001)
California (2668)
Canada (989)
China (265)
Colorado (122)
Connecticut (127)
Europe (62863)
Florida (407)
Georgia (92)
Illinois (282)
Indiana (154)
Japan (81)
Maryland (452)
Massachusetts (1920)
Michigan (133)
Minnesota (172)
New Jersey (857)
New York (890)
North Carolina (549)
Northern California (1209)
Ohio (105)
Pennsylvania (588)
South America (717)
Southern California (1021)
Texas (390)
Washington State (298)
454,625 Results for "palo alto research center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Xerox Announces Donation of Palo Alto Research Center (PARC) to SRI International
Xerox Holdings Corporation announced the donation of the Palo Alto Research Center to SRI International, a nonprofit research institute behind some of the world’s most impactful deep tech advancements.
April 24, 2023
·
4 min read
Biotech Bay
Mispro to Expand Contract Vivarium Network to Palo Alto
Innovative contract vivarium organization, Mispro, plans to expand its vivarium research labs network to Palo Alto’s prestigious Stanford Research Park.
May 18, 2023
·
2 min read
Neuroscience
Alto Depression Therapy Fails Mid-Stage Trial, 9 Months After IPO
Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning failure called to mind Acelyrin, which faced a similar fate last year.
October 23, 2024
·
4 min read
·
Annalee Armstrong
Drug Development
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of ALTO-101, a novel PDE4 inhibitor in development for the treatment of cognitive impairment associated with schizophrenia (CIAS).
June 20, 2024
·
6 min read
Biotech Bay
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York.
May 29, 2024
·
1 min read
Biotech Bay
SRI International Will Receive Renowned Research Center PARC from Xerox
SRI International, an independent nonprofit research institute behind countless cutting-edge technological advances, announced it will receive the Palo Alto Research Center, a Xerox company and technology pioneer.
April 24, 2023
·
3 min read
Drug Development
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).
April 23, 2024
·
7 min read
Biotech Bay
AbTherx Opens Antibody Discovery Technologies Research Center
AbTherx, Inc., a biotechnology company with innovative technologies that enable and accelerate antibody discovery, announced the opening of its new antibody discovery technologies research center.
June 18, 2024
·
3 min read
Business
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO).
May 21, 2024
·
3 min read
Drug Development
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.
April 3, 2024
·
4 min read
1 of 45,463
Next
